Celecoxib Patent Expiration
Celecoxib is Used for reducing inflammation and treating various types of arthritis. It was first introduced by Upjohn Us 2 Llc
Celecoxib Patents
Given below is the list of patents protecting Celecoxib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyscoxa | US12678405 | Sep 17, 2045 | Carwin Pharm Assoc | |
| Elyxyb | US10376527 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Elyxyb | US10722456 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Elyxyb | US10799517 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Elyxyb | US9572819 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Elyxyb | US9795620 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Elyxyb | US9949990 | Oral composition of celecoxib for treatment of pain | May 27, 2036 | Scilex Pharms |
| Celebrex |
US5760068 (Pediatric) | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Dec 02, 2015
(Expired) | Upjohn |
| Celebrex |
USRE44048 (Pediatric) | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Dec 02, 2015
(Expired) | Upjohn |
| Celebrex | US5760068 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Jun 02, 2015
(Expired) | Upjohn |
| Celebrex | USRE44048 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Jun 02, 2015
(Expired) | Upjohn |
| Celebrex |
US5466823 (Pediatric) | Substituted pyrazolyl benzenesulfonamides |
May 30, 2014
(Expired) | Upjohn |
| Celebrex |
US5563165 (Pediatric) | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
May 30, 2014
(Expired) | Upjohn |
| Celebrex | US5466823 | Substituted pyrazolyl benzenesulfonamides |
Nov 30, 2013
(Expired) | Upjohn |
| Celebrex | US5563165 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Nov 30, 2013
(Expired) | Upjohn |
Celecoxib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Celecoxib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
